

Supplementary Information


Supplementary Table 1. Expression of cytokines, chemokines, and growth factors in the serum of $\alpha 1,3\text{GalT-KO}$ mice immunized with Gal $\alpha 3\text{LN-HSA}$, Gal $\alpha 3\text{LN-HSA+LMPLA}$, or HSA+LMPLA, and challenged with *T. cruzi* TCTs.

Immunization group	Immunized-challenged, mean (picograms/mL)	SD	Challenged only, mean (picograms/mL)	SD	<i>p</i> value ^a	Fold-change ^b
Gal$\alpha 3\text{LN-HSA}$						
IL-1 α	143.50	19.40	465.70	5.60	0.000026	0.3
IL-4	0.82	0.20	1.95	0.10	0.002772	0.4
IL-6	39.92	4.10	71.75	1.60	0.000525	0.6
IL-12 p70	29.76	4.00	50.07	0.90	0.002555	0.6
LIF	4.49	0.20	6.38	0.30	0.000754	0.7
MCP-1 (CCL2)	114.20	19.86	234.60	3.50	0.001295	0.5
MIP-1 α (CCL3)	53.06	3.09	66.50	1.70	0.005246	0.8
RANTES (CCL5)	58.91	5.01	85.76	2.60	0.002377	0.7
KC (CXCL1)	111.10	26.01	207.70	9.25	0.008348	0.5
LIX (CXCL5)	593.50	114.97	1011.00	126.04	0.014973	0.6
MIG (CXCL9)	951.10	96.96	1641.00	19.80	0.000707	0.6
G-CSF	86.23	5.29	232.40	0.00	0.000003	0.4
VEGF	2.94	0.14	3.32	0.09	0.029723	0.9
Gal$\alpha 3\text{LN-HSA+LMPLA}$						
IL-1 α	110.60	7.20	465.70	5.60	<0.000001	0.2
IL-2	57.85	10.50	18.37	0.20	0.007487	3.1
IL-4	4.11	0.70	1.95	0.10	0.015703	2.1
IL-9	491.80	46.50	243.40	24.10	0.002419	2.0
IL-12 p40	20.31	3.90	30.81	0.00	0.022701	0.7
IL-15	187.40	12.50	143.10	4.80	0.009889	1.3
MCP-1 (CCL2)	137.30	40.37	234.60	3.50	0.032521	0.6
MIP-1 α (CCL3)	97.12	6.18	66.50	1.70	0.002846	1.5
MIP-1 β (CCL4)	67.49	13.03	100.70	1.84	0.027568	0.7
RANTES (CCL5)	56.05	9.49	85.76	2.60	0.014567	0.7
MIG (CXCL9)	994.30	194.90	1641.00	19.80	0.011540	0.6
G-CSF	95.12	12.13	232.40	0.00	0.000112	0.4
VEGF	13.40	4.82	3.32	0.09	0.049323	4.0
HSA+LMPLA						
IL-1 α	86.50	10.10	465.70	5.60	0.000001	0.2
IL-6	41.81	4.20	71.75	1.60	0.000730	0.6
IL-12 p70	33.44	5.40	50.07	0.90	0.014692	0.7
IL-12 p40	18.32	4.70	30.81	0.00	0.024089	0.6
IL-17	3.84	0.40	4.83	0.13	0.037465	0.8
LIF	9.12	0.90	6.38	0.30	0.015019	1.4
MCP-1 (CCL2)	130.20	33.11	234.60	3.50	0.013730	0.6
MIP-1 β (CCL4)	70.94	13.74	100.70	1.84	0.044984	0.7
MIG (CXCL9)	1230.00	180.91	1641.00	19.80	0.038901	0.7


^a Student's *t*-test was used for comparing animals immunized with Gal $\alpha 3\text{LN-HSA+/-LMPLA}$ or HSA+LMPLA, followed by parasite challenge, with a group of animals subjected to challenge only. Cytokines, chemokines, and growth factors were measured at the experimental endpoint (32 dpi) in two biological replicates, each containing two technical replicates, as described in Methods section.

^b Ratio of protein levels of immunized-challenged group to challenged-only group. The red-to-green gradient indicates fold-change from lower to higher values. Only statistically significant reduction or increase in protein levels in the immunized-challenged group in comparison with challenged-only group are shown.



Supplementary Figures




Supplementary Figure 1. Kinetics of IgE and IgA elicited by immunization with Gal α 3LN-HSA, Gal α 3LN-HSA+LMPLA, or HSA+LMPLA. Prior to the CL-ELISA, each serum sample was pre-incubated with a 15- μ L bead suspension mixture of protein A-Sepharose 4B and protein G-Sepharose, both fast flow (A:G, 1:1, v/v), and recombinant HSA (1 mg/mL), for 1 h at 37°C. Reactivity of mouse sera from α 1,3GalT-KO mice immunized with Gal α 3LN-HSA, Gal α 3LN-HSA+LMPLA, or HSA+LMPLA, was evaluated by CL-ELISA, using Gal α 3LN-HSA as immobilized antigen. Error bars indicate S.E.M. of triplicate determinations. Samples no longer available are indicated (#).



Supplementary Figure 2. Kinetics of background response to different antigens (Gal α 3LN-HSA, HSA, BSA, and casein) elicited by immunization with Gal α 3LN-HSA. CL-ELISA was performed as described in Methods. Error bars indicate S.E.M. of triplicate determinations. The α -Gal-specific reactivity is indicated (#).

a**b**

Supplementary Figure 3. Gating strategies used for flow cytometry. **(a)** Gating strategy was performed with samples from a group of unstimulated naïve mice (α 1,3GalT-KO C57Bl/6) using forward and side scatter properties to eliminate debris. CD4⁺ and CD8⁺ T cells were both pre-gated with CD3⁺, and CD44⁺ T cells were pre-gated with CD3⁺CD4⁺ or CD3⁺CD8⁺ T cells. The same gating strategy set for naïve samples was applied to all experimental samples shown in manuscript. **(b)** Example of experimental sample of a group of mice (α 1,3GalT-KO C57Bl/6) immunized with Gal α 3LN+HSA and infected with *T. cruzi*, then splenocytes were stimulated ex-vivo with Gal α 3LN+HSA antigen as described in Methods section



Supplementary Figure 4. Representative immunohistochemistry analysis of CD3⁺, CD4⁺, and CD8⁺ T cells in the cardiac tissues at experimental endpoint. **(a)** Specific antibody staining of CD3⁺, CD4⁺, and CD8⁺ T cells. In each animal group, the top panels show the whole tissue sections, at 1.5x magnification (long horizontal bar: 2 mm); the bottom panels indicate zoomed sections from rectangular insets in the top panels, at 40x magnification (short horizontal bar: 50 μm). **(b)** Quantitative analysis of one representative mouse from each group. For consistency, only ventricle areas were evaluated. Predominant inflammatory cells were CD3⁺ T cells, and CD8⁺ T cells were higher than CD4⁺ T cells present in the sections examined.